Which Weight Loss Products Really Work?

In our recent articles we have covered the mechanism of action and effectiveness of several phentermine-based drugs. In today’s post we’ll take a closer look at a bunch of other weight loss solutions that enjoy popularity around the globe: Xenical, Proactol and Byette are on our list.


Orlistat, the main active substance of Xenical, aims at prevention of fat absorption in the body. The medication blocks lipase enzyme that splits fat just before its absorption starts. As a result, up to 30% fats you consume with foods are not absorbed and get excreted with feces. The preparation also contributes to a more extensive producing of the accumulated fat reserves.

With Xenical you can press for up to 30% weight reduction. One of its most crucial advantages is that it is not absorbed by the blood, hence causes no addiction and adversely affects the body. However, one of the most best-selling drugs has a range of unpleasant adverse reactions, e.g. oily discharge from the straight intestine, flatulence, increased bowel movements, bloating, diarrhea, stomach ache and etc.


Proactol is another decent tool for losing extra pounds, despite its natural composition, its weight loss capabilities have been clinically proven. Unlike Xenical, Proactol is a completely organic product, so it beats its rival in terms of side effects – the risks of adverse reactions in Proactol is almost reduced to nothing (with the exception of hypersensitivity to its components); however, the drug is less effective against the background of its pharmaceutical competitor.

The mechanism of action in Proactol is similar to Xenical: it is aiming at prevention of the absorption of fats through binding to the before the process starts. Proactol enables you to stick to your regular diet without the risk of gaining weight; however, an effective weight loss program implies reconsidering the diet plan and eliminating carb and fat-rich products. Proactol binding to fats equals up to 28%, meaning you can press for spectacular weight loss results in the long run (the drug is approved for long-term use).  In addition, Proactol also suppresses appetite and decreases cholesterol levels.


Byetta is an offbeat solution: it comes in a rare, portable injector form, featuring two dosage options. The drug is administered in the thigh, abdomen or upper arm. The starting dose is 5 mg, which is administered 2 times per day.

In the US, this drug, like Glucophage (siofor, metformin), is the drug prescribed for obesity treatment on a regular basis.

The active ingredient of Byetta is a synthetic analogue of the protein, contained in the saliva of a Gila lizard. Such lizards live without food for prolonged periods of time, and when studying this ability scientists have discovered a new substance considerably slowing down the process of emptying the stomach. In weight loss this ability was reduced in a pharmaceutical form, allowing to suppress appetite and reduce food intake, respectively. In addition, it inhibits gastric motility, which leads to slower emptying. But its main feature, for which, in fact it is primarily used, is a hypoglycemic (lowering blood sugar) action. Some studies have raised hopes that Byetta can be used not only as a cure for diabetes, but also as a tool for weight loss. The average weight loss results recorded in these observations were quite modest, as a rule not exceeding 11 pounds (5 kg) within the period of up to 12 months.


In 2012, the FDA has approved a new substance for weight loss – lorcaserin, currently available under the brand name Belviq. This drug acts on serotonin receptors in the brain, helping to feel satiated, while consuming smaller amounts of food. In the US lorcaserin – prescription medicine (the drug subjected to control under the Controlled Substances Act). The active substance represents an antagonist of serotonin 5-HT2C receptors and its action is based on the blockage of the urge of hunger, enabling patients to feel more satiated and thus consuming less foods.

Belviq is designed to treat obesity and maintain body weight only as a part of a complex therapy, involving lifestyle changes, including dietary restrictions and/or physical activity. Just like phentermine medications, it is indicated for patients with the body mass index exceeding 30 kg/m2.

Belviq is taken orally at a dosage of 10 mg twice a day. If the patient’s weight in the first 12 weeks is not decreased by at least 5%, the course of treatment should be stopped, as the likelihood of a noteworthy weight loss with continued treatment is insignificant.